Trial Profile

Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study HIT-HGG-CilMetro - A Clinical Phase II Trial of the HIT-HGG Study Group.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cilengitide (Primary) ; Temozolomide (Primary)
Indications Anaplastic astrocytoma; Diffuse intrinsic pontine glioma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
Focus Therapeutic Use
Acronyms HGG-Cil-Metro; HIT-HGG-CilMetro

05 Oct 2021 Status changed from discontinued to completed.
13 Jun 2014 European Clinical Trials Database record mentions trial status as ongoing.
24 Apr 2014 Status changed from recruiting to discontinued, as per ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com